Voriconazole Intravenous (Iv) Solution Suppliers & Bulk Manufacturers
Available Forms: Intravenous (IV) Solution
Available Strengths: 200 mg/100 mL
Reference Brands: Vfend(US & EU)
Category:
Anti-fungal
Voriconazole IV inhibits fungal cytochrome P450 14α-demethylase, disrupting ergosterol synthesis essential for fungal cell membranes. It provides broad-spectrum antifungal activity, rapid systemic treatment, and excellent tissue penetration. Benefits include high efficacy against invasive fungi like Aspergillus, making it vital for treating severe fungal infections.
Voriconazole Intravenous (IV) Solution is available in Intravenous (IV) Solution
and strengths such as 200 mg/100 mL.
Sourced from GMP-certified and ISO-compliant manufacturers, this API meets
global pharmacopeia standards (USP/EP/JP as applicable). Ideal for pharmaceutical
formulation and commercial manufacturing, Voriconazole Intravenous (IV) Solution is supplied in
bulk quantities with complete regulatory support including DMF, COA, and MSDS.
|
Technical Specifications & Supply Details
|
| Lead Time |
7 to 60 days (depending on batch size & schedule) |
| MOQ |
As per manufacturer’s batch size |
| COA |
Available with every batch |
| Regulatory Dossier / DMF |
Available upon request |
| Export Documentation |
FSC, COA, Manufacturing License, Product Permission |
| Standards |
IP, BP, USP |
| Certifications |
WHO-GMP, EU-GMP, USFDA (as applicable) |
Voriconazole Intravenous (IV) Solution can be exported to over 30 countries across Asia, Africa, Europe,
and Latin America. Flexible packaging, competitive pricing, and a verified supplier
network make Pharmatradz a trusted sourcing partner for pharmaceutical companies
and contract manufacturers worldwide.
Product Description:
Voriconazole IV solution is approved in the EU and US for severe fungal infections. In the EU, Pfizer’s Vfend IV is regulated by EMA, backed by dossiers demonstrating safety, efficacy, and quality. In the US, FDA approval is based on comprehensive clinical data, biosimilarity assessments, and ongoing pharmacovigilance. Both regions require detailed regulatory dossiers for initial approval and continuous safety monitoring. For expert assistance with regulatory dossiers, submissions, and compliance, visit PharmaTradz, your trusted partner in pharmaceutical regulatory solutions. We support efficient market access for voriconazole IV formulations, ensuring adherence to European and American standards for safe, effective antifungal therapy.
Disclaimer: By continuing to browse, you agree to the terms of use of this website and the Trade Marks displayed, in compliance with the provisions of the Trademark Act, 1999, Section 30 and 30(1) under 'Fair use.'
The Trade Mark owner has been correctly identified under the heading Manufacturer / TM Owner as required by the Act.
Back to Listing